Logo image of ALBOA.PA

BOA CONCEPT SACA (ALBOA.PA) Stock Fundamental Analysis

EPA:ALBOA - Euronext Paris - Matif - FR0011365907 - Common Stock - Currency: EUR

21  0 (0%)

Fundamental Rating

3

Overall ALBOA gets a fundamental rating of 3 out of 10. We evaluated ALBOA against 0 industry peers in the Unkown industry. ALBOA may be in some trouble as it scores bad on both profitability and health. ALBOA is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

ALBOA had negative earnings in the past year.
In the past year ALBOA had a positive cash flow from operations.
ALBOA.PA Yearly Net Income VS EBIT VS OCF VS FCFALBOA.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 0 1M -1M 2M 3M

1.2 Ratios

Industry RankSector Rank
ROA -0.25%
ROE -0.42%
ROIC N/A
ROA(3y)10.92%
ROA(5y)N/A
ROE(3y)20.7%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ALBOA.PA Yearly ROA, ROE, ROICALBOA.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 0 10 20 30

1.3 Margins

ALBOA's Gross Margin has been stable in the last couple of years.
The Profit Margin and Operating Margin are not available for ALBOA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 77.69%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.02%
GM growth 5YN/A
ALBOA.PA Yearly Profit, Operating, Gross MarginsALBOA.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 0 20 40 60

More info and screens

3

2. Health

2.1 Basic Checks

ALBOA does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, ALBOA has about the same amount of shares outstanding.
ALBOA has a better debt/assets ratio than last year.
ALBOA.PA Yearly Shares OutstandingALBOA.PA Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 200K 400K 600K 800K
ALBOA.PA Yearly Total Debt VS Total AssetsALBOA.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 5M 10M 15M 20M

2.2 Solvency

An Altman-Z score of 2.33 indicates that ALBOA is not a great score, but indicates only limited risk for bankruptcy at the moment.
ALBOA has a Debt/Equity ratio of 0.38. This is a healthy value indicating a solid balance between debt and equity.
Industry RankSector Rank
Debt/Equity 0.38
Debt/FCF N/A
Altman-Z 2.33
ROIC/WACCN/A
WACC8.53%
ALBOA.PA Yearly LT Debt VS Equity VS FCFALBOA.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 0 5M 10M 15M

2.3 Liquidity

ALBOA has a Current Ratio of 4.31. This indicates that ALBOA is financially healthy and has no problem in meeting its short term obligations.
A Quick Ratio of 3.60 indicates that ALBOA has no problem at all paying its short term obligations.
Industry RankSector Rank
Current Ratio 4.31
Quick Ratio 3.6
ALBOA.PA Yearly Current Assets VS Current LiabilitesALBOA.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 5M 10M 15M 20M

More info and screens

5

3. Growth

3.1 Past

The earnings per share for ALBOA have decreased strongly by -103.16% in the last year.
ALBOA shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -44.18%.
The Revenue has been growing by 41.61% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-103.16%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-184.17%
Revenue 1Y (TTM)-44.18%
Revenue growth 3Y41.61%
Revenue growth 5YN/A
Sales Q2Q%-53.47%

3.2 Future

Based on estimates for the next years, ALBOA will show a very strong growth in Earnings Per Share. The EPS will grow by 86.81% on average per year.
ALBOA is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 10.08% yearly.
EPS Next Y-4.08%
EPS Next 2Y86.81%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year4.12%
Revenue Next 2Y10.08%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
ALBOA.PA Yearly Revenue VS EstimatesALBOA.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 5M 10M 15M 20M
ALBOA.PA Yearly EPS VS EstimatesALBOA.PA Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 0.5 1 1.5

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ALBOA. In the last year negative earnings were reported.
ALBOA is valuated reasonably with a Price/Forward Earnings ratio of 11.92.
Compared to an average S&P500 Price/Forward Earnings ratio of 22.10, ALBOA is valued a bit cheaper.
Industry RankSector Rank
PE N/A
Fwd PE 11.92
ALBOA.PA Price Earnings VS Forward Price EarningsALBOA.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 -100 -200

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ALBOA.PA Per share dataALBOA.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5 10 15

4.3 Compensation for Growth

ALBOA's earnings are expected to grow with 86.81% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y86.81%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

ALBOA does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BOA CONCEPT SACA

EPA:ALBOA (3/7/2025, 7:00:00 PM)

21

0 (0%)

Chartmill FA Rating
GICS SectorN/A
GICS IndustryGroupN/A
GICS IndustryN/A
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst Owners0.26%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap20.37M
Analysts86.67
Price Target34.68 (65.14%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 11.92
P/S 1.82
P/FCF N/A
P/OCF 21.65
P/B 1.29
P/tB 1.43
EV/EBITDA N/A
EPS(TTM)-0.07
EYN/A
EPS(NY)1.76
Fwd EY8.39%
FCF(TTM)-8.55
FCFYN/A
OCF(TTM)0.97
OCFY4.62%
SpS11.56
BVpS16.32
TBVpS14.66
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -0.25%
ROE -0.42%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 77.69%
FCFM N/A
ROA(3y)10.92%
ROA(5y)N/A
ROE(3y)20.7%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)15.91%
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.02%
GM growth 5YN/A
F-Score4
Asset Turnover0.42
Health
Industry RankSector Rank
Debt/Equity 0.38
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 2336.22%
Cap/Sales 82.34%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.31
Quick Ratio 3.6
Altman-Z 2.33
F-Score4
WACC8.53%
ROIC/WACCN/A
Cap/Depr(3y)249.67%
Cap/Depr(5y)N/A
Cap/Sales(3y)7.25%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-103.16%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-184.17%
EPS Next Y-4.08%
EPS Next 2Y86.81%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-44.18%
Revenue growth 3Y41.61%
Revenue growth 5YN/A
Sales Q2Q%-53.47%
Revenue Next Year4.12%
Revenue Next 2Y10.08%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-121.16%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-43.07%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-229.47%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-67.95%
OCF growth 3YN/A
OCF growth 5YN/A